APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
about
SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infectionAID and APOBECs span the gap between innate and adaptive immunityNew insights into an X-traordinary viral proteinSAMHD1-Dependent and -Independent Functions of HIV-2/SIV Vpx ProteinSAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphatesMolecular mechanisms of HIV immune evasion of the innate immune response in myeloid cellsSuppression of APOBEC3-mediated restriction of HIV-1 by VifMacrophage polarization in health and diseaseNMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificityEndogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2nA DNA sequence recognition loop on APOBEC3A controls substrate specificityDifferent mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanismsIntrinsic cellular defenses against human immunodeficiency virusesTransient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes.Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity.17β-estradiol protects primary macrophages against HIV infection through induction of interferon-alpha.Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.Novel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro.Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death.Distinct characteristics of endometrial and decidual macrophages and regulation of their permissivity to HIV-1 infection by SAMHD1.Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulationSelect host restriction factors are associated with HIV persistence during antiretroviral therapy.APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophagesEradication of HIV-1 from the macrophage reservoir: an uncertain goal?The Frequency of Cytidine Editing of Viral DNA Is Differentially Influenced by Vpx and Nucleosides during HIV-1 or SIVMAC Infection of Dendritic Cells.Stress-activated Dendritic Cells (DC) Induce Dual Interleukin (IL)-15- and IL1β-mediated Pathways, Which May Elicit CD4+ Memory T Cells and Interferon (IFN)-stimulated Genes.APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans.Antiviral gene expression in psoriasis.Retroelements versus APOBEC3 family members: No great escape from the magnificent sevenBiochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.Technical advance: liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human diseaseAPOBEC3 Proteins in Viral Immunity.Functional analysis of the relationship between Vpx and the restriction factor SAMHD1.SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferonsInhibition of reverse transcriptase activity increases stability of the HIV-1 core.TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection.
P2860
Q21089603-B2B6344B-650B-4762-91A3-7C781A32D060Q21131084-9C243523-7D23-440A-9803-A53E39541F75Q21131105-9E2E62A7-4A2D-408F-AA78-FCAD33E9C93FQ21131138-F4E5B503-3E31-4D47-B296-9F34435A7661Q24624362-0AAEE08D-F746-4AB4-B1C5-89858FE34302Q27022978-5466BCAB-0A54-49F9-BF81-7766ECA85D4CQ27025150-A7D104E9-BD73-4B65-AE90-16101FB2C789Q27027054-59EE2CB9-37EF-4183-BAC4-9CBA880D7160Q27678249-EC6DA2A6-A852-4983-ACDF-D203467F6EB3Q28481286-8389049A-9CE0-43B1-9018-7E1643BE67E8Q28538801-6AE0D6DA-B99B-40A3-83E1-CD687FBF813CQ28541264-CB44556A-C576-459C-8D29-84761CC0E621Q28659575-B1EEAB12-EA88-45CA-9F0A-6119E7C12A33Q30853937-022FA9E1-900F-407C-83E2-19A1E3798D7AQ33630551-01E49FD3-2FE2-4FE5-82FC-54726C7AED7DQ33631612-BF4F3DAD-FA5F-4DA2-AED0-1482941124FAQ33650603-23AF9410-D5F9-4FD4-A038-FDFBA805DA2DQ33651576-C12D3994-0DCE-42C3-BF51-D571F36CF127Q34091405-6B067511-2D68-4A17-B961-9EEB466300F3Q34263217-EC40BB61-9FA1-4F54-8614-46A0ABB3D4D7Q34323296-89B06B7B-50F2-41E4-A805-CAED289A497AQ34974240-42CC2C11-C2F0-4FAD-9A16-42AA2DB669E5Q34991106-019E18C8-27FF-4DDD-ADDD-4E8DB04174BFQ35041156-95B82521-097D-4461-9B61-6145DE245218Q35271996-E77099E7-3A49-459F-A08B-5686D72BA223Q35543248-662692FD-563E-454A-8E43-873AC458A270Q35544355-5E222DDC-9985-462F-96FF-61559C9878BCQ35819276-134CA099-ACCB-4613-B3B2-C6BAFFA4BB7CQ35860660-A874C459-9632-43F2-BEB5-B4C0D5C9CF11Q36031782-FBB495A4-FCBD-4442-8292-514B16166B8AQ36086989-4548C717-B99A-4B26-A22D-4ED3042A506CQ36162443-363711DB-B62C-4D2C-A61A-9437C3643376Q36216511-15AFA23E-58CF-4BB0-8656-5180029AA731Q36246121-FD780F82-7404-4121-A482-BCE5D6A221BEQ36263411-E2CD45F6-CD86-4E2F-AF2B-B77DEDD632E5Q36436068-0488572C-B23F-4F74-AB61-D871E5D1BB85Q36480173-52111539-D30A-4620-A94F-48B157F3F540Q36506926-84C1678D-661D-4908-A297-ACFFDC87DE0AQ36578830-F794637D-0366-4376-BAB7-79F3F1B1CF4BQ36688084-766AAD36-6C6E-4EF0-BD62-E816BBA0E7FF
P2860
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@ast
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@en
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@nl
type
label
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@ast
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@en
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@nl
prefLabel
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@ast
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@en
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.
@nl
P2093
P2860
P1433
P1476
APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells
@en
P2093
Delphine Muriaux
Gregory Berger
Guillaume Fargier
Jean-Luc Darlix
Serge Bouaziz
Stéphanie Cordeil
Stéphanie Durand
Xuan-Nhi Nguyen
P2860
P304
P356
10.1371/JOURNAL.PPAT.1002221
P577
2011-09-22T00:00:00Z